Shanghai Xian Wei Yi Yao Ke Ji You Xian Gong Si

Xianwei Pharma is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of innovative ophthalmic therapies. Founded by industry veterans with extensive experience in ocular drug discovery, the company focuses on addressing unmet medical needs in retinal diseases and myopia. Their lead candidate, XW-001, is a small molecule multi-kinase inhibitor designed for the treatment of wet age-related macular degeneration and diabetic macular edema. Xianwei Pharma leverages its expertise in ocular pharmacology and drug delivery to create a robust pipeline of next-generation treatments. The company has successfully secured significant venture capital funding from prominent investors to advance its clinical programs.